Who Owns Acuvue?
Acuvue is owned by Johnson & Johnson Vision Care, Inc., a wholly-owned subsidiary of Johnson & Johnson, a publicly traded American healthcare conglomerate listed on the New York Stock Exchange under the ticker JNJ. Johnson & Johnson launched Acuvue in 1987 as the world's first disposable contact lens. Acuvue is the number one selling contact lens brand globally by volume. Johnson & Johnson is headquartered in New Brunswick, New Jersey, USA.
Parent Company
Johnson & Johnson
Founded
1987
Status
Publicly Traded
Headquarters
Jacksonville, Florida, USA
Who Owns Acuvue?
- Parent Company: Johnson & Johnson
- Ownership Type: Wholly owned
- Company Type: Publicly Traded
- Stock Ticker: NYSE: JNJ
| Brand | Parent Company | Ownership Type |
|---|---|---|
| Acuvue | Johnson & Johnson | Wholly owned |
History of Acuvue
- Founded: 1987
- Founders: Johnson & Johnson Vision Care Team
Johnson & Johnson's vision care division, working with clinical researchers and lens material scientists, developed the first planned replacement disposable soft contact lens in the mid-1980s. The key innovation was demonstrating that wearing a fresh contact lens more frequently improved both eye health and comfort compared to extended-wear reusable lenses that required daily cleaning and care.
Acuvue launched in the United States in 1987 as a seven-day disposable lens, intended to be worn for one week and then discarded. The seven-day replacement schedule represented a paradigm shift from the then-standard practice of using extended-wear soft lenses for months or years with daily cleaning. The product was received well by optometrists and consumers who valued the convenience and hygiene improvements.
In 1993, J&J introduced Acuvue 1-Day, the first daily disposable contact lens. Daily disposables became the fastest-growing segment in the contact lens market and are now the dominant lens modality in many developed markets. J&J Vision Care continued expanding its Acuvue daily disposable portfolio with successively improved materials and optical designs.
In 1999, J&J launched Acuvue OASYS, a high-oxygen silicone hydrogel lens designed for two-week or monthly replacement. OASYS became one of the best-selling contact lens products globally, benefiting from the higher oxygen transmissibility of silicone hydrogel materials compared to earlier hydrogel lenses.
Subsequent innovations in the Acuvue portfolio include Acuvue OASYS 1-Day (a daily silicone hydrogel lens launched in 2015), Acuvue Vita (a monthly silicone hydrogel lens), and Acuvue Oasys Max 1-Day (launched in 2022 with a new HydraLuxe Plus technology for digital device users). J&J Vision Care has also developed Acuvue contact lenses with UV blocking capability, which have received FDA clearance as Class II medical devices.
About Johnson & Johnson
Johnson & Johnson delivered exceptional 2025 results, with CEO Joaquin Duato describing it as a "catapult year" fueled by the strongest portfolio and pipeline in the company's history. Q4 2025 reported sales grew 9.1% to $24.6 billion, with operational growth of 7.1% and adjusted operational growth of 6.1%. Full-year 2025 sales reached $94.2 billion, up 6.0% year-over-year, demonstrating strong momentum across both business segments.
Financial Performance Overview shows Johnson & Johnson's remarkable growth trajectory. The company achieved extraordinary earnings growth with Q4 2025 EPS of $2.10 reported and $2.46 adjusted, while full-year 2025 EPS reached $11.03 reported and $10.79 adjusted. This performance reflects the effectiveness of Johnson & Johnson's strategic focus on innovation and operational excellence across its diverse healthcare portfolio.
Segment Performance demonstrated balanced growth across Johnson & Johnson's two main business segments. The Innovative Medicine segment achieved Q4 2025 sales of $15.8 billion, up 10.0% year-over-year with operational growth of 7.9%. The MedTech segment reached $8.8 billion in Q4 2025 sales, up 7.5% year-over-year with operational growth of 5.8%. For the full year, Innovative Medicine generated $60.4 billion in sales while MedTech contributed $33.8 billion, showing strong performance across pharmaceutical and medical device businesses.
Geographic Performance revealed robust growth across key markets. U.S. sales reached $14.2 billion in Q4 2025, up 7.5% year-over-year with operational growth of 7.5%. International markets achieved $10.4 billion in Q4 2025 sales, up 11.3% year-over-year with operational growth of 6.6%. For the full year, U.S. sales totaled $53.8 billion while international markets contributed $40.4 billion, demonstrating Johnson & Johnson's global reach and market penetration.
2026 Guidance reflects management confidence in continued growth momentum. Johnson & Johnson issued strong guidance for 2026, projecting estimated reported sales of $100.5 billion (6.7% growth at midpoint) and adjusted EPS of $11.53 (6.9% growth at midpoint). This guidance suggests continued strong performance across both Innovative Medicine and MedTech segments, supported by the company's robust pipeline and market-leading products.
Medical Innovation Achievements in 2025 were particularly noteworthy, highlighting Johnson & Johnson's leadership in developing breakthrough treatments. Significant innovations included the approval of CAPLYTA for major depressive disorder, representing a major advancement in mental health treatment. The company also secured approval for RYBREVANT FASPRO plus LAZCLUZE for non-small cell lung cancer, demonstrating continued leadership in oncology therapeutics.
Landmark Clinical Data further strengthened Johnson & Johnson's market position. The company reported landmark data for TECVAYLI plus DARZALEX FASPRO as a potential standard of care as early as second line for patients with relapsed/refractory multiple myeloma. This clinical evidence supports Johnson & Johnson's position in treating complex hematological conditions and reinforces the company's reputation for developing innovative cancer therapies.
Strategic Acquisitions enhanced Johnson & Johnson's capabilities and pipeline strength. The acquisition of Halda Therapeutics during 2025 expanded the company's therapeutic capabilities and strengthened its pipeline of future medical breakthroughs across multiple therapeutic areas. This strategic acquisition demonstrates Johnson & Johnson's commitment to investing in innovative technologies and treatments that address unmet medical needs.
Surgical Technology Innovation marked Johnson & Johnson's expansion into advanced medical technology. The submission of the OTTAVA Robotic Surgical System represents the company's entry into the rapidly growing robotic surgery market, positioning Johnson & Johnson to compete with established players in minimally invasive surgical procedures. This innovation reflects the company's strategy of leveraging its medical expertise across multiple healthcare segments.
Operational Excellence contributed significantly to Johnson & Johnson's strong performance. The company achieved operational growth of 5.3% for the full year 2025, with adjusted operational growth of 4.2%, demonstrating effective management of costs and operational efficiency. This operational performance enabled Johnson & Johnson to convert revenue growth into strong earnings improvement and cash generation.
Research and Development Investment continued to drive Johnson & Johnson's innovation pipeline. The company's commitment to R&D investment, spending billions annually on pharmaceutical innovation and medical technology, has created a robust pipeline of future products across multiple therapeutic areas. This investment strategy has positioned Johnson & Johnson for sustained growth and market leadership in healthcare innovation.
Market Leadership Position was reinforced across multiple healthcare segments. Johnson & Johnson maintained dominant positions in oncology, immunology, neuroscience, cardiovascular, surgery, and vision care, with each of these six key therapeutic areas contributing to the company's overall growth and market presence. This diversified leadership reduces dependency on any single therapeutic area and provides multiple growth drivers.
Cash Generation and Financial Strength enabled Johnson & Johnson to pursue strategic initiatives while maintaining shareholder returns. The company generated approximately $19.7 billion in free cash flow for full year 2025, supporting strategic acquisitions, R&D investment, and capital returns to shareholders. This strong cash generation provides financial flexibility for future growth opportunities.
Regulatory Success in 2025 demonstrated Johnson & Johnson's ability to navigate complex regulatory environments and secure approvals for innovative treatments. The company's success in obtaining regulatory approvals for new indications and products reflects the strength of its clinical development programs and regulatory expertise.
Patient Impact remains central to Johnson & Johnson's mission and performance. The company's innovations in 2025, including new treatments for major depressive disorder and various cancers, directly impact patient lives and address critical unmet medical needs. This patient-centric approach drives both commercial success and fulfillment of Johnson & Johnson's broader healthcare mission.
Johnson & Johnson's 2025 performance demonstrates the effectiveness of its strategy focusing on medical innovation, operational excellence, and global market expansion. The combination of strong financial results, breakthrough innovations, and robust pipeline positions the company for continued leadership in the global healthcare industry.
- Founded: 1886
- Headquarters: New Brunswick, New Jersey, USA
- Company Type: Publicly Traded
- Stock: NYSE: JNJ
- Revenue: approximately $88.8 billion (FY2025)
- Employees: Approximately 131,000
Where Is Acuvue Made / Based?
- Headquarters: Jacksonville, Florida, USA
- Manufacturing / Operations: Jacksonville, Florida, USA, Limerick, Ireland, Wuxi, China
Acuvue Sustainability & Ethics
Johnson & Johnson publishes an annual ESG Performance Summary disclosing its environmental, social, and governance performance. J&J has set a goal of achieving carbon neutrality across its own operations (Scopes 1 and 2) by 2030 and to reduce value chain (Scope 3) emissions by 20 percent by 2025 relative to a 2016 baseline.
Contact lens packaging and blister packs represent a significant waste challenge for the industry. J&J Vision Care has implemented blister pack recycling programs in partnership with TerraCycle in selected markets, allowing consumers to return used Acuvue blister packs for recycling. As of May 2025, these programs operate in the United States, United Kingdom, and select other markets. J&J has committed to making Acuvue packaging recyclable or refillable in major markets.
Johnson & Johnson Vision Care's manufacturing facilities in Jacksonville and Limerick operate under ISO 14001 environmental management certification. J&J is a member of the Ellen MacArthur Foundation's New Plastics Economy Global Commitment.
Awards & Recognition
The Acuvue OASYS with Transitions Light Intelligent Technology lens received recognition as an innovative product after its 2019 launch. The lens incorporates photochromic technology that causes the lens to automatically darken in response to UV and high-energy visible light exposure, providing a combined vision correction and light management function that had not previously been available in a contact lens format.
J&J Vision Care has received recognition from eye care professional organizations in various markets for its professional education programs and clinical research contributions. Acuvue lenses have received FDA clearance for UV blocking as a supplemental benefit on multiple product lines, which has been noted by eye health organizations as a meaningful product innovation.
Specific independently verifiable third-party consumer product awards for Acuvue are documented across various markets, though comprehensive consolidated records are not available in a single public source as of May 2025.
Acuvue Recalls & Controversies
Acuvue OASYS 1-Day Recall (2019): Johnson & Johnson Vision Care issued a voluntary recall in July 2019 for approximately 30 million Acuvue OASYS 1-Day with HydraLuxe lenses. The recall was initiated due to a manufacturing defect that could cause some lenses to have an incorrect base curve or diameter, potentially resulting in discomfort or vision problems. The recall was limited to specific lot numbers and was managed through contact lens providers and optometrists who had dispensed the affected products. The FDA classified the recall as Class II, meaning the product may cause temporary adverse health consequences but is unlikely to cause permanent injury.
Pricing and Antitrust: J&J Vision Care and other major contact lens manufacturers have faced antitrust scrutiny and consumer complaints regarding minimum advertised price (MAP) policies that restricted online retailers from selling contact lenses below manufacturer-set minimum prices. In 2015, the U.S. Department of Justice investigated unilateral pricing policies in the contact lens market. Retailers and consumer groups argued these policies raised prices for consumers. The contact lens industry reached a class action settlement in 2016 valued at approximately 100 million USD, though J&J Vision Care's specific role and settlement contribution were not separately disclosed.
China Market Data Privacy: J&J Vision Care, like other companies operating in China, is subject to China's Personal Information Protection Law (PIPL), which has raised compliance questions for multinational companies about how consumer data collected in China must be stored and processed. No specific enforcement action against J&J Vision Care under PIPL has been publicly documented as of May 2025.
Contact Lens Prescription Requirements Debate: J&J and other contact lens manufacturers have been involved in ongoing industry debates about contact lens prescription validity periods and whether consumers should be able to purchase lenses without a valid prescription. Consumer groups and some online retailers have argued for easier access, while eye care professionals and manufacturers have supported prescription requirements on safety grounds.
Brands Owned by Johnson & Johnson
- Aveeno - American brand of skincare and hair care products specializing in natural ingred...
- Band-Aid - American adhesive bandage brand invented in 1921, owned by Kenvue Inc. Band-Aid ...
- Benadryl - American brand of antihistamine medication used to treat allergies, itching, and...
- Carefree - American brand of feminine hygiene liners and pads, manufactured and marketed by...
- Clean & Clear - American brand of acne treatment and skincare products specializing in oil-contr...
- Johnson's Baby - American brand of baby care products specializing in gentle formulations for inf...
- Motrin - American brand of ibuprofen pain relief medication owned by Kenvue, the consumer...
- Neosporin - American brand of antibiotic ointment and topical wound care products containing...
- Rembrandt - American brand of whitening toothpaste and oral care products specializing in te...
- RoC - American brand of dermatological skincare products specializing in anti-aging an...
- Stayfree - Feminine hygiene brand of pads and liners owned by Kenvue globally, with North A...
- Tylenol - American brand of pain relief medication and analgesic drugs, flagship product o...
- Zyrtec - American brand of cetirizine antihistamine medication used to treat allergies wi...
Acuvue Ownership: Pros & Cons
Advantages
- +J&J's global manufacturing infrastructure gives Acuvue access to large-scale, high-quality production at multiple international sites with FDA and equivalent regulatory oversight
- +J&J's brand recognition and trust in healthcare markets provides Acuvue with credibility among eye care professionals and consumers that newer brands struggle to match
- +J&J Vision Care's investment in clinical research, professional education, and product development sustains Acuvue's technology leadership in the market
- +J&J's global distribution network enables Acuvue to be available in more than 100 countries through optometrists, optical retail chains, and online platforms
Considerations
- -The 2019 Acuvue OASYS 1-Day recall raised manufacturing quality questions and required significant operational and reputational management
- -Contact lens blister pack waste represents an environmental liability that is difficult to address at scale with current recycling infrastructure in most markets
- -Antitrust concerns related to MAP pricing policies have resulted in legal costs and reputational scrutiny regarding whether J&J's pricing strategies benefit consumers
- -Silicone hydrogel lens technology is now widely available from competitors at similar price points, reducing Acuvue's materials technology advantage that existed in the early 2000s
Frequently Asked Questions About Acuvue
Sources & Further Reading
Where to Buy
Disclosure: We may earn commission from purchases
Acuvue on AmazonCompetitors to Acuvue
These competing brands operate in the same categories and provide similar products or services. Compare key attributes to understand market positioning and competitive landscape.
| Brand | Parent Company | Country | Founded | Market Position | Primary Market | Gender Target |
|---|---|---|---|---|---|---|
| Alcon | Switzerland | 1945 | Leader | Global | Unisex |
Competitive Analysis
Market Positioning: Acuvue competes with 1 brands in the same categories, ranging from mass market to luxury positioning.
Geographic Distribution: Competitors are headquartered across multiple regions, indicating global competition in this market segment.
Brand Heritage: Competitor brands range from established heritage brands to newer market entrants, with founding years spanning several decades.
Johnson & Johnson Stock Information
Jobs at Johnson & Johnson
Latest News About Acuvue
Related Articles About Acuvue
View more articles
Your Entire Medicine Cabinet Might Be J&J
Tylenol, Band-Aid, Listerine, Neutrogena, Aveeno, Benadryl. Johnson & Johnson's consumer health portfolio is extensive. Here is a complete look at the brands now under Kenvue.
Pfizer vs Johnson & Johnson: Pharma Brand Portfolios Compared
Pfizer and Johnson & Johnson are two of the most recognizable names in healthcare. But their brand portfolios look nothing alike. Here is a complete breakdown of what each company owns, how they got there, and what sets them apart.
How Johnson & Johnson Built Its Portfolio Over 100 Years
From Band-Aids to blockbuster drugs, J&J spent a century building one of healthcare's largest empires. Then it split in two. Now Kenvue is being acquired for $48.7 billion.
People Also Searched
Discover popular brands and companies in the Healthcare & Pharmaceuticals category and related searches from other users.
Accutane
Prescription isotretinoin brand developed by Roche and approved by the FDA in 1982 for severe nodular acne. Roche discontinued the brand name in the United States in 2009; the drug continues as Roaccutane in international markets.
Activase
Activase (alteplase) is a prescription thrombolytic medication manufactured by Genentech, a wholly-owned subsidiary of Roche. Used to treat acute ischemic stroke, heart attack, and pulmonary embolism.
Adcetris
Prescription antibody-drug conjugate treatment for classical Hodgkin lymphoma and CD30-expressing peripheral T-cell lymphomas, co-developed by Seagen and licensed to Takeda Pharmaceutical.